期刊文献+

胃癌外周血淋巴细胞亚群表达水平对患者生存率的影响 被引量:7

Impact of lymphocytes subgroups in peripheral blood on survival rate of patients with gastric cancer
原文传递
导出
摘要 目的探讨胃癌患者外周血淋巴细胞亚群表达与生存率的关系。方法用流式细胞仪检测833例胃癌首诊患者外周血的淋巴细胞亚群CD3^+、CD4^+、CD8^+、CD4^+/CD8^+、CD19^+、CD25^+、CD44^+及NK^+细胞.并根据96名健康对照者的平均检测值分为高表达组和低表达组.比较各亚群高表达组与低表达组患者的生存率。结果与健康对照者相比.胃癌患者CD3^+、CD8^+低表达。而CD4^+,CDl9^+,CD25^+、CD4^+/CD8^+、CD44^+,NK^+高表达(P〈0.05)。CD19^+高表达与低表达者分别为444例和389例,3年生存率为36.4%和18.5%,差异有统计学意义(P〈0.05):而其他7种淋巴细胞亚群表达水平则与患者生存率无关(均P〉0.05)。结论与健康人群相比,胃癌患者外周血淋巴细胞亚群发生显著变化.其中CDl9^+高表达患者具有明显的生存优势。 Objective To study the change of lymphocyte subgroups in the peripheral blood of patients with gastric carcinoma and its association with survival. Methods Flow cytometry was used to examine the subgroups of lymphocytes (CD3^+, CD4^+, CD8^+, CD4^+/CD8^+, CD19^+, CD25^+, CD44^+ and NK cells) in the peripheral blood of 833 gastric carcinoma patients prior to any therapy. Patients were divided into the high expression group and lower expression group according to the average test values of 96 healthy control subjects. Survival rate was compared between the two groups. Results Compared with control group, the levels of CD3^+ and CD8^+ T cell in patients were significantly lower, while the levels of CD4^+, CD19^+, CD25^+, CD4^+/CD8^+, CD44^+, and NK^+ cells were significantly. The differences were statistically significant (P〈0.05). Three-year survival rates of gastric cancer patients with high CD19^+ expression (n=444) and cases with low CD19^+ expression (n=389) were 36.4% and 18.5%, respectively (P〈0.05). The expressions of other seven types of lymphocytes were not associated with survival rates (all P〉0.05). Conclusions Significant changes in lymphocyte subgroups exist in the peripheral blood of patients with gastric carcinoma. Patients with high CD19^+ expression have better survival.
出处 《中华胃肠外科杂志》 CAS 北大核心 2011年第10期796-798,共3页 Chinese Journal of Gastrointestinal Surgery
基金 基金项目:浙江省科技计划资助项目(2009C33143)
关键词 胃肿瘤 流式细胞术 淋巴细胞亚群 抗原 CDL9 生存率 Stomach neoplasms Flow cytometry Lymphocyte subsets Antigens, CDI9 Survival rate
  • 相关文献

参考文献6

二级参考文献39

  • 1李强,张轶,张奕,陈雪华,李建芳,顾琴龙,朱正纲,刘炳亚.小鼠I-A^kII类分子限制性MAGE-3T表位筛选[J].现代免疫学,2005,25(1):19-23. 被引量:3
  • 2李强,张轶,陈雪华,顾琴龙,朱正纲,刘炳亚.小鼠MHCⅠ类分子限制性MAGE-3多肽表位筛选[J].上海第二医科大学学报,2005,25(7):657-660. 被引量:2
  • 3Ikeda H,Chamoto k,tsuj T,et al. The critical role of type-1 innate and acquired immunity in tumor immunotherapy [J]. Cancer Sci,2004,95(9) :697-703.
  • 4余传霖,叶天显,陆德源,等.现代免疫学:肿瘤免疫学[M].上海医科大学出版社,上海,1998:1014-1066.
  • 5吕昌龙,李殿俊,李一.医学免疫学[M].6版.北京:高等教育出版社,2007:192.
  • 6Hsu M M, Lin B L. Characterization of T cell subsets using monoclonal antihodies in nasopharyngeal carcinoma patients [J]. Ann Oto Rhinol laryngol,1986,95(3 pt 1): 298-301.
  • 7Kuss l, Hathway B, Ferris R L, et al. Decreased absolute counts of T lymphocyte subsets and their ralation to disease in squamous cell carcinoma of the head and neck [J]. Clin Cancer Res,2004,10(ll) :3755-3762.
  • 8徐从高,张茂宏,杨兴季,等.癌--肿瘤学原理和实践[M].5版.济南:山东科学技术出版社,2000:49-70.
  • 9曹广文,杜平.现代癌症生物学[M].2版.北京:军医出版社,1999:20.
  • 10陈灏珠.实用内科学[M]11版[M].北京:人民卫生出版社,2002.1367.

共引文献81

同被引文献61

  • 1何裕隆.胃癌病理分型研究进展[J].中国实用外科杂志,2005,25(7):438-440. 被引量:28
  • 2许杜娟,陈敏珠.黄芪多糖的抑瘤作用及其机制[J].中国医院药学杂志,2005,25(10):923-925. 被引量:96
  • 3姜成,郑全英,肖何.消癌平抗肿瘤药理实验与临床研究进展[J].上海中医药杂志,2007,41(7):78-79. 被引量:24
  • 4Hotta K,Oyama T.A comparison of endoscopic submucosal dissection(ESD)for early gastric neoplasms between high-volume and low-volume centres:multi-center retrospective questionnaire study conducted by the Nagano ESD Study Group[J].InternMed,2010,49(4):253-259.
  • 5贺用和,林红声.中药与化疗结合治疗癌症的进展.中华新医学,2002,3(4):355-357.
  • 6Nakajima T. Gastric cancer treatment guidelines in Japan [ J ]. Gastric Cancer,2002,5 ( l ) : 1 - 5.
  • 7D'Acquisto F, Crompton T. CD3 + D4 - CD8 - (double negative)T cells: saviours or villains of the immune response [ J ]. Biochem Pharmacol, 2011, 82 (4) :333 -40.
  • 8Kim E Y, Juvet S C, Zhang L. Regulatory CD4 ( - ) CD8 ( - ) double negative T cells[J]. Methods Mol Biol, 2011, 677:85 - 98.
  • 9Cho W C, Leung K N. In vitro and in vivo immunomodulating and e effects of astragalus membranaceus [ J ]. J Ethno- pharmacol,2007,113 ( 1 ) : 132 - 41.
  • 10Cho W C, Leung K N. In vitro and in vivo anti-tumor effects of As- tragalus membranaceus [ J ]. Cancer Lett, 2007, 252 ( 1 ) : 43 - 54.

引证文献7

二级引证文献69

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部